Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: A. Biondo, T. A. Yap, L. Yan, A. Patnaik, I. Fearen, R. D. Baird, K. P. Papadopoulos, L. M. Delgado, A. Taylor, L. Lupinacci, S. C. Blackman, S. Decordova, M. Tall, S. Heaton, M. D. Garrett, D. Sullivan, J. S. De Bono, A. W. Tolcher
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2589824760